Sudden cardiac death in children is one of the most devastating conditions that can be encountered in acute cardiac care. Intracardiac device therapy, providing prompt and effective treatment in malignant ventricular arrhythmia or in severe conduction abnormalities, is a promising tool to reduce the incidence of this fatal condition. However, the implementation of device-based therapy in the pediatric population is currently limited by the lack of clinical studies on large number of subjects. As a result, indications for device therapy in pediatric patients are still unclear in many circumstances. There are also several particularities related to device implantation in pediatric age, such as the somatic growth leading to a mismatch between chamber size and lead length, or the difficulties of implantation technique in children with small body weight. This study aims to present an update on the current advantages and limitations of device-based therapy for treating severe malignant arrhythmia or conduction disorders in children at risk for sudden cardiac death.
BACKGROUND
Device therapy has a well-established role in the treatment of various heart diseases in the adult population. Intracardiac pacemakers are widely used for treating atrioventricular conduction disturbances, while intracardiac defibrillators (ICD) are first-line therapies for treating severe arrhythmia and preventing sudden cardiac death.
In parallel, resynchronization devices have been validated as efficient tools for treating heart failure in selected cases with electrical dyssynchrony, restoring contraction synchronism by simultaneous stimulation of the left and right ventricle. While the role of device therapy at adult age is widely accepted nowadays, many controversies still exist regarding the role of implantable devices in children with congenital heart diseases (CHD). One of the main reasons for this is the lack of large clinical trials in a pediatric population and the significant heterogeneity of this group. 
SUDDEN CARDIAC DEATH IN CHILDHOOD
Sudden cardiac death (SCD) is the most severe type of cardiovascular emergency that can be encountered in childhood.
In children, the incidence of SCD has been reported to be approximately 1/100,000 individuals, being usually encountered in pediatric patients with various forms of ventricular tachycardia (VT) or presenting postoperative arrhythmia after surgical repair of CHD. 3 Other frequently identified causes include cardiomyopathies, myocarditis, coronary artery abnormalities, or conduction system anomalies. 3 Sudden cardiac death in childhood occurs also in association with CHD. In the CHD group, there are several specific diseases that are associated with a higher risk for severe ventricular arrhythmia and SCD. One of these high-risk subgroups is represented by children with CHD and inherited channelopaties. 4 Other diseases associated more often with a higher arrhythmic risk are the tetralogy of Fallot and the transposition of the great arteries (TGA). 5 After surgical treatment for tetralogy of Fallot, the incidence of ventricular arrhythmia has been reported to be as high as 1.2% to 3.0% per decade. 6 TGA is associated with a higher risk for SCD, which can result from malignant ventricular arrhythmia or rapid ventricular response to atrial fibrillation, and also with an increased frequency of abnormalities of the conduction system, which have been reported in as much as 25% of children with TGA. 6, 7 Patients with CHD surviving to adult age present also a relatively high incidence of ventricular arrhythmia, approximately 0.1% to 0.2% per year, and implantation of an ICD device in these patients can be life-saving. 8 In many cases, a genetic predisposition exposes the children to a higher risk of various heart diseases. For instance, angiotensin gene polymorphism has been identified in secondary pulmonary arterial hypertension in children with congenital heart disease. 9 This kind of genetic inheritance has been described in several types of malignant arrhythmia and SCD in pediatric patients. Genetic testing and counseling may have a significant impact on the decision-making process with respect to indicating ICD therapy to children from families carrying an in- 
ImPLANTATION Of INTRACARDIAC DEvICES IN CHD -A CHALLENGING PROCEDURE
The complexity of cardiac anatomy in CHD can make implantation of an intracardiac device a very challenging procedure. Frequently, children with CHD have various types of intracardiac communications that make it difficult to guide the leads to the target area. Furthermore, the risk of complications following the surgical correction of CHD is not negligible, and these postoperative complications can significantly impact the evolution of the patients. 21 Device therapy in neonates or young infants is even more challenging due to their low weight. In a recent report, 34% of implants at age below 1 year were associated with lead malfunction events. 22 However, successful pacemaker implantation has been reported even in small children weighing less than 10 kg. 23 This indicates that device therapy in this age category is extremely challenging, and a proper selection of devices and implantation technique is essential for improving the success rate and to preserve the functionality of the device on a longer term.
ImPLANTABLE PACEmAKERS fOR TREATING CONDUCTION DISORDERS IN PEDIATRIC AGE
Cardiac conduction disorders can occur in structurally normal hearts, in various types of CHD, or following the surgical correction of complex structural heart diseases. 
CONCLUSION
In conclusion, device therapy can improve survival and quality of life in children at risk for SCD, by treating severe arrhythmia or conduction disorders that can have devastating consequences. In certain conditions, the implantation of a proper device can be extremely challenging, especially in infants with small weight or in the case of complex CHD with difficult anatomy. This therapy could be life-saving, providing urgent and effective treatment in several forms of major cardiovascular emergencies;
however, larger studies are required to validate the most effective type of device or implantation technique in the complex and heterogenous group of children with CHD
